SUPPORT CANADIANS LIVING WITH CANCER
Supportive therapy for multiple myeloma
Multiple myeloma and its treatments can lead to other health problems. Doctors give supportive therapy to help prevent or control these problems.
Corticosteroids used to treat multiple myeloma are artificial steroid hormones. The corticosteroids most often used to treat multiple myeloma are prednisone and dexamethasone (Decadron, Dexasone). These drugs are often combined with chemotherapy to help chemotherapy work better and to lessen the side effects of chemotherapy. They are sometimes used alone if a person is too sick to take chemotherapy to help slow the growth of myeloma cells and lower the amount of M-protein in the blood. Corticosteroids can also help relieve pain and improve nerve function in people with spinal cord compression.
Multiple myeloma can destroy bone. This can cause bones to become weak and even break (called a fracture). Bisphosphonates are a class of drug that can slow down bone destruction and help keep bones strong. Bisphosphonates also help reduce bone pain and prevent high levels of calcium in the blood (called hypercalcemia) from bone destruction, which can lead to kidney failure.
Bisphosphonates are given about once a month for about 2 years. The most common bisphosphonates used in people with multiple myeloma are:
- pamidronate (Aredia)
- zoledronic acid (Zometa, Zoledronate)
- clodronate (Bonefos, Ostac)
If after 2 years the cancer is in remission, your doctor may stop bisphosphonate treatment. But if you are still having treatment for multiple myeloma after 2 years, you may get bisphosphonate treatment less frequently (for example, once every 3 months).
See your dentist before and while taking bisphosphonates
Bisphosphonates can lead to death of the jaw bone, a condition called osteonecrosis of the jaw. This is a rare side effect of bisphosphonates, and doctors don’t know why it happens. It is more common in people who have dental surgery such as tooth extractions or periodontal surgery such as implants. People should have a complete dental exam before taking bisphosphonates. It is very important for people with multiple myeloma who take bisphosphonates to have regular dental checkups. Dental or periodontal surgery should be done before taking bisphosphonates.
Learn more about bisphosphonates.
Erythrocyte growth factors
Erythrocyte growth factors are drugs that help the body make more red blood cells. The drugs include epoetin alfa (Eprex, Erythropoietin) and darbepoetin (Aranesp). These drugs help to treat anemia, a common problem that develops in people with multiple myeloma. Erythrocyte growth factors can help relieve the symptoms of anemia including weakness, dizziness and fatigue. They also improve a person’s hemoglobin level and quality of life. Erythrocyte growth factors can help a person avoid a blood transfusion.
Learn more about erythrocyte growth factors.
Drugs to prevent infection
People with multiple myeloma often develop infections. Antibiotics may be given to prevent and treat infections. People with multiple myeloma may also get immunoglobulins from a donor by vein to help boost antibodies in the blood to help fight infection. Your doctor may also recommend that you get vaccines to help prevent infections.
Plasmapheresis is a procedure that helps remove M-protein from the blood to treat hyperviscosity. An M-protein is an immunoglobulin that is found in high amounts in a person with multiple myeloma. Too much M-protein in the blood can cause the blood to thicken and prevent it from moving through the body properly. This condition is called hyperviscosity.
Information on specific drugs
For more detailed information on specific drugs, go to sources of drug information.
Any steroid hormone that acts as an anti-inflammatory by reducing swelling and lowering the body’s immune response (the immune system’s reaction to the presence of foreign substances).
Corticosteroids are made by the adrenal gland. They can also be produced in the lab.
A reduction in the number of healthy red blood cells.
Together we can reduce the burden of cancer
Last year, we only had the resources available to fund 40% of high-priority research projects. Imagine the impact we could have if we were able to fund 100%.